7. Validation and Testing

Institutions should use rigorous methods to validate their models and document those methods and results. In particular, they should routinely perform tests to assess and determine whether the model generates discriminatory harm. Institutions are encouraged to make the results of such tests public.
Principle: Principles for Algorithmic Transparency and Accountability, Jan 12, 2017

Published by ACM US Public Policy Council (USACM)

Related Principles

1. Accountability and Transparency

o ADP believes that human oversight is core to providing reliable ML results. We have implemented audit and risk assessments to test our models as the baseline of our oversight methodologies. We continue to actively monitor and improve our models and systems to ensure that changes in the underlying data or model conditions do not inappropriately affect the desired results. o ADP provides information as to how we handle personal data in the relevant privacy statement that is made available to our clients’ employees, consumers or job applicants.

Published by ADP in ADP: Ethics in Artificial Intelligence, 2018 (unconfirmed)

2. Transparency

For cognitive systems to fulfill their world changing potential, it is vital that people have confidence in their recommendations, judgments and uses. Therefore, the IBM company will make clear: When and for what purposes AI is being applied in the cognitive solutions we develop and deploy. The major sources of data and expertise that inform the insights of cognitive solutions, as well as the methods used to train those systems and solutions. The principle that clients own their own business models and intellectual property and that they can use AI and cognitive systems to enhance the advantages they have built, often through years of experience. We will work with our clients to protect their data and insights, and will encourage our clients, partners and industry colleagues to adopt similar practices.

Published by IBM in Principles for the Cognitive Era, Jan 17, 2017

4. Risk Assessment and Management

Regulatory and non regulatory approaches to AI should be based on a consistent application of risk assessment and risk management across various agencies and various technologies. It is not necessary to mitigate every foreseeable risk; in fact, a foundational principle of regulatory policy is that all activities involve tradeoffs. Instead, a risk based approach should be used to determine which risks are acceptable and which risks present the possibility of unacceptable harm, or harm that has expected costs greater than expected benefits. Agencies should be transparent about their evaluations of risk and re evaluate their assumptions and conclusions at appropriate intervals so as to foster accountability. Correspondingly, the magnitude and nature of the consequences should an AI tool fail, or for that matter succeed, can help inform the level and type of regulatory effort that is appropriate to identify and mitigate risks. Specifically, agencies should follow the direction in Executive Order 12866, “Regulatory Planning and Review,”to consider the degree and nature of the risks posed by various activities within their jurisdiction. Such an approach will, where appropriate, avoid hazard based and unnecessarily precautionary approaches to regulation that could unjustifiably inhibit innovation.

Published by The White House Office of Science and Technology Policy (OSTP), United States in Principles for the Stewardship of AI Applications, Jan 13, 2020

3 Ensure transparency, explainability and intelligibility

AI should be intelligible or understandable to developers, users and regulators. Two broad approaches to ensuring intelligibility are improving the transparency and explainability of AI technology. Transparency requires that sufficient information (described below) be published or documented before the design and deployment of an AI technology. Such information should facilitate meaningful public consultation and debate on how the AI technology is designed and how it should be used. Such information should continue to be published and documented regularly and in a timely manner after an AI technology is approved for use. Transparency will improve system quality and protect patient and public health safety. For instance, system evaluators require transparency in order to identify errors, and government regulators rely on transparency to conduct proper, effective oversight. It must be possible to audit an AI technology, including if something goes wrong. Transparency should include accurate information about the assumptions and limitations of the technology, operating protocols, the properties of the data (including methods of data collection, processing and labelling) and development of the algorithmic model. AI technologies should be explainable to the extent possible and according to the capacity of those to whom the explanation is directed. Data protection laws already create specific obligations of explainability for automated decision making. Those who might request or require an explanation should be well informed, and the educational information must be tailored to each population, including, for example, marginalized populations. Many AI technologies are complex, and the complexity might frustrate both the explainer and the person receiving the explanation. There is a possible trade off between full explainability of an algorithm (at the cost of accuracy) and improved accuracy (at the cost of explainability). All algorithms should be tested rigorously in the settings in which the technology will be used in order to ensure that it meets standards of safety and efficacy. The examination and validation should include the assumptions, operational protocols, data properties and output decisions of the AI technology. Tests and evaluations should be regular, transparent and of sufficient breadth to cover differences in the performance of the algorithm according to race, ethnicity, gender, age and other relevant human characteristics. There should be robust, independent oversight of such tests and evaluation to ensure that they are conducted safely and effectively. Health care institutions, health systems and public health agencies should regularly publish information about how decisions have been made for adoption of an AI technology and how the technology will be evaluated periodically, its uses, its known limitations and the role of decision making, which can facilitate external auditing and oversight.

Published by World Health Organization (WHO) in Key ethical principles for use of artificial intelligence for health, Jun 28, 2021

4 Foster responsibility and accountability

Humans require clear, transparent specification of the tasks that systems can perform and the conditions under which they can achieve the desired level of performance; this helps to ensure that health care providers can use an AI technology responsibly. Although AI technologies perform specific tasks, it is the responsibility of human stakeholders to ensure that they can perform those tasks and that they are used under appropriate conditions. Responsibility can be assured by application of “human warranty”, which implies evaluation by patients and clinicians in the development and deployment of AI technologies. In human warranty, regulatory principles are applied upstream and downstream of the algorithm by establishing points of human supervision. The critical points of supervision are identified by discussions among professionals, patients and designers. The goal is to ensure that the algorithm remains on a machine learning development path that is medically effective, can be interrogated and is ethically responsible; it involves active partnership with patients and the public, such as meaningful public consultation and debate (101). Ultimately, such work should be validated by regulatory agencies or other supervisory authorities. When something does go wrong in application of an AI technology, there should be accountability. Appropriate mechanisms should be adopted to ensure questioning by and redress for individuals and groups adversely affected by algorithmically informed decisions. This should include access to prompt, effective remedies and redress from governments and companies that deploy AI technologies for health care. Redress should include compensation, rehabilitation, restitution, sanctions where necessary and a guarantee of non repetition. The use of AI technologies in medicine requires attribution of responsibility within complex systems in which responsibility is distributed among numerous agents. When medical decisions by AI technologies harm individuals, responsibility and accountability processes should clearly identify the relative roles of manufacturers and clinical users in the harm. This is an evolving challenge and remains unsettled in the laws of most countries. Institutions have not only legal liability but also a duty to assume responsibility for decisions made by the algorithms they use, even if it is not feasible to explain in detail how the algorithms produce their results. To avoid diffusion of responsibility, in which “everybody’s problem becomes nobody’s responsibility”, a faultless responsibility model (“collective responsibility”), in which all the agents involved in the development and deployment of an AI technology are held responsible, can encourage all actors to act with integrity and minimize harm. In such a model, the actual intentions of each agent (or actor) or their ability to control an outcome are not considered.

Published by World Health Organization (WHO) in Key ethical principles for use of artificial intelligence for health, Jun 28, 2021